PROMIX (NCT00957125) is an academic, non-randomized, single arm, multicenter phase II study which was conducted at five centers in Sweden during 2008-2011. Study PI is Thomas Hatschek. In total, 150 patients were enrolled.

Patients with HER2-negative breast cancer and tumors larger than 20 mm were enrolled in the study and were treated with neoadjuvant epirubicin in combination with docetaxel, both administered every 3 weeks, for six cycles. Bevacizumab every 3 weeks was added to cycles 3-6 in case of non-complete clinical response. Core biopsies were obtained at baseline before treatment initiation and after two cycles of neoadjuvant treatment.

ARIADNE trial overview

Relevant publications:

  1. “Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.”.
    C. Kim et al.
    Cell, vol. 173, no. 4, pp. 879–893.e13, May 2018
  2. “Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer.”.
    A. Matikas et al.
    Oncoimmunology, vol. 7, no. 9, p. e1466017, 2018
  3. “Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer.”.
    A. Matikas et al.
    ESMO Open, vol. 6, no. 2, p. 100076, Apr. 2021
  4. “Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer.”.
    K. Wang et al.
    Nature Communications, vol. 15, no. 1, p. 3837, May 2024